Elastrin Therapeutics Inc.

Elastrin Therapeutics Announces Newly Formed Scientific Advisory Board

Retrieved on: 
Monday, January 17, 2022

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.

Key Points: 
  • Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.
  • We are fortunate to work with such an amazing group of medical scientists, cardiovascular experts and pharma executives on our Scientific Advisory Board, said Dr. Matthias Breugelmans, CEO of Elastrin Therapeutics.
  • Elastrin is a prime example of what Kizoo is looking for in its investments: Not delaying an age-related disease but reversing it, said Patrick Burgermeister, Partner at Kizoo Technology Capital and member of Elastrin Therapeutics Board of Directors.
  • Elastrin Therapeutics Scientific Advisory Board is comprised of:
    Prof. Charles O'Neill, MD: Dr. ONeill has had an active basic and clinical research program in vascular calcification for the past 20 years and has published over 45 articles on this subject.

Elastrin Therapeutics Strengthens its Leadership Team by Appointing Pedro M. Quintana Diez, MD as Chief Medical Officer

Retrieved on: 
Wednesday, April 28, 2021

b"Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the appointment of Pedro M. Quintana Diez, MD as Chief Medical Officer.

Key Points: 
  • b"Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the appointment of Pedro M. Quintana Diez, MD as Chief Medical Officer.
  • \xe2\x80\x9cHis deep knowledge of cardiovascular research and medicine from both an industry and academic perspective is a strong addition to Elastrin preparing for clinical trials.
  • Prior to joining Elastrin Therapeutics, Pedro served as Chief Medical Officer of Sensory Sciences LLC and held VP and leadership positions at Grunenthal, Abbvie and ParinGenix, where he developed clinical strategies and plans across all phases of clinical development, through life-cycle management key decisions.
  • Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries.

Kizoo Provides Seed Funding for Elastrin Therapeutics to Develop Groundbreaking New Technology Capable of Reversing Tissue and Organ Calcification

Retrieved on: 
Thursday, March 4, 2021

Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.

Key Points: 
  • Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.
  • It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level.
  • Elastrins lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the treatment of heart valve and vascular calcification.
  • The Elastrin team has developed a platform that can restore vascular health by removing pathological calcification specifically from sites where elastin has been degraded.